PDF(Pubmed)
Abstract：
Fosfomycin is a bactericidal drug recommended as an alternative treatment for canine bacterial cystitis, particularly in cases involving multidrug-resistant (MDR) infections when no other options are available. In this study, minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of fosfomycin were determined against 79 clinical E. coli isolates using the agar dilution method. The susceptibility rate of E. coli to fosfomycin was 86.06%, with MIC50 and MIC90 values of 4 mg/L and 96 mg/L, respectively. MPC50 and MPC90 values were 64 mg/L and 192 mg/L. Using pharmacokinetic (PK) data from dogs given a single 80 mg/kg oral dose of fosfomycin, the area under the curve per MIC50 (AUC0-24/MIC50) was 85.79 with time above MIC50 (T > MIC50) exceeding 50%. In urine, the AUC0-24/MIC50 was 10,694.78, and the AUC0-24/MPC90 was 222.81, with T > MPC90 extending beyond 24 h. Therefore, fosfomycin exhibited significant antibacterial activity against canine uropathogenic E. coli, including MDR strains, at concentrations below the susceptible MIC breakpoint. However, the high MPC values, especially the MPC90, indicate the critical importance of performing susceptibility testing for fosfomycin and maintaining ongoing resistance monitoring.
摘要：
磷霉素是一种推荐作为犬细菌性膀胱炎替代治疗的杀菌药物，特别是在没有其他选择的情况下，涉及多药耐药（MDR）感染。在这项研究中,采用琼脂稀释法测定磷霉素对79株临床大肠杆菌的最低抑菌浓度(MIC)和突变预防浓度(MPC)。大肠杆菌对磷霉素的敏感率为86.06%,MIC50和MIC90值为4mg/L和96mg/L，分别。MPC50和MPC90值分别为64mg/L和192mg/L。使用来自狗的药代动力学（PK）数据，给予单次80mg/kg口服剂量的磷霉素，每个MIC50的曲线下面积(AUC0-24/MIC50)为85.79,时间高于MIC50(T>MIC50)超过50%。在尿液中，AUC0-24/MIC50为10,694.78，AUC0-24/MPC90为222.81，T>MPC90延伸超过24小时。因此，磷霉素对犬尿路致病性大肠杆菌具有显著的抗菌活性，包括MDR菌株，在低于易感MIC断点的浓度下。然而,高MPC值，尤其是MPC90,表明进行磷霉素药敏试验和持续的耐药性监测至关重要.
